Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Double-Blind Placebo-Controlled Phase 3 Study of AMG 162 (Denosumab) in Men Receiving Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer
2004-000512-17Phase 3Completed
- Sponsor
- Amgen
- Start
- Jul 2004
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa), osteopenia and osteoporosis comparing Denosumab with Placebo (2 arms). Primary endpoint: Percentage change from baseline in lumbar spine bone mineral density at month 24. Started Jul 2004; status: completed.
02
Drugs
denosumab
03
Conditions
prostate cancer (PCa)osteopeniaosteoporosis
Beyond the preview
Go deeper on 2004-000512-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000512-17.